🔴 AIM ImmunoTech is trading 5.1% down in pre-market — reason for decline remains unconfirmed

AIM ImmunoTech is trading 5.1% down now at $0.24 in pre-market, with the reason for the decline unconfirmed.

• No new company-specific announcement was identified for August 21, 2026.
• The latest substantial update was its August 10 second-quarter report, highlighting progress toward planned Phase 3 pancreatic-cancer development; that news is stale and does not directly explain the decline.
• The broader market is modestly higher pre-market, so the move does not clearly track overall index sentiment.